Nanofiber-Mediated Sustained Delivery of Triiodothyronine: Role in Angiogenesis.
angiogenesis
nanofibers
polycaprolactone
triiodothyronine
wound healing
Journal
AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111
Informations de publication
Date de publication:
12 Feb 2019
12 Feb 2019
Historique:
received:
17
11
2018
accepted:
31
01
2019
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
6
4
2019
Statut:
epublish
Résumé
Angiogenesis is a vital component of the orchestrated wound healing cascade and tissue regeneration process, which has a therapeutic prominence in treatment of ischemic vascular diseases and certain cardiac conditions. Based on its eminence, several strategies using growth factors have been studied to initiate angiogenesis. However, growth factors are expensive and have short half-life. In this work, sustained release of triiodothyronine, which plays a crucial role in stimulating growth factors and other signaling pathways that are instrumental in initiating angiogenesis, has been attempted through electrospun polycaprolactone nanofibers. This delivery system enabled the slow and sustained delivery of triiodothyronine into the micro-environment, reducing seepage of excess into systemic circulation and eliminating the necessity of repeated dosage forms. It was observed that triiodothyronine-incorporated nanofibers exhibited favorable interaction with cells (phalloidin staining of actin filaments) and also enhanced the rate of endothelial proliferation, migration, and adhesion. The angiogenic potential of these nanofibers was further corroborated through chorioallantoic membrane and rat aortic ring assay (demonstrating cell sprouting area of 3.3 ± 0.71 mm
Identifiants
pubmed: 30756201
doi: 10.1208/s12249-019-1326-y
pii: 10.1208/s12249-019-1326-y
doi:
Substances chimiques
Biocompatible Materials
0
Drug Carriers
0
Polyesters
0
Triiodothyronine
06LU7C9H1V
polycaprolactone
24980-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM